## Claims

- 1. A biocompatible block copolymer having at least two chemically different block units obtainable by linear polycondensation of a diol with a component selected from the group of the same diol, an  $\alpha, \omega$ -dihydroxypolyester or an  $\alpha, \omega$ -dihydroxypolyester or an  $\alpha, \omega$ -dihydroxypolyether in the presence of diisocyanate, diacid halide or phosgene,
- where the diol is obtainable by transesterification of  $\alpha, \omega$ -dihydroxy-[oligo(3-(R)-hydroxybutyrate)-ethylene-oligo-3-(R)-hydroxybutyrate) with diglycolide and/or dilactide and/or caprolactone or mixtures thereof,
- the  $\alpha, \omega$ -dihydroxypolyester is obtainable by transesterification of poly-(R)-hydroxyvaleric acid or copolymers thereof with 3-hydroxyvaleric acid with ethylene glycol,
- the  $\alpha, \omega$ -dihydroxypolyether is selected from the group of  $\alpha, \omega$ -dihydroxypoly(oxytetramethylene),  $\alpha, \omega$ -dihydroxypoly(oxyethylene) and copolymers of ethylene glycol and propylene glycol.
- The biocompatible block copolymer as claimed in 25 claim 1, where the block copolymer is poly[poly[ $\alpha$ ,  $\omega$ -dihydroxy-[oligo(3-(R)hydroxybutyrate) -stat-glycolide) -ethylene-oligo-(3-(R)-hydroxybutyrate-stat-glycolide) ]alt-2,2,4trimethylhexamethylene 1,6-diisocyanate]-co-poly-30 [dihydroxy[oligo-glycolide-ran-ε-caprolactone]ethylene-(oligo-glycolide-ran-ε-caprolactone)]alt-2,2,4-trimethylenehexaethylene 1,6-isocyanate].
- 3. The biocompatible block copolymer as claimed in either of the preceding claims, characterized in that it is biodegradable.
  - 4. The biocompatible block copolymer as claimed in

any of the preceding claims, characterized in that it is degradable in the human and in the animal body.

- 5 5. The biocompatible block copolymer as claimed in any of the preceding claims, characterized in that it is melt-processible.
- 6. The biocompatible block copolymer to any of the preceding claims, obtainable by linear cocondensation with further low molecular weight compounds having additional functional groups.
- 7. The biocompatible block copolymer as claimed in claim 6, characterized in that it comprises chemically bonded pharmaceutical active substances or diagnostics.
- 8. A shaped article comprising a biocompatible block copolymer as claimed in any of the preceding claims.
- 9. A medical or veterinary medical implant comprising a biocompatible block copolymer as claimed in any of the preceding claims.
  - 10. An implant as claimed in claim 9, characterized in that it has a porous structure.
- 30 11. The implant as claimed in either of claims 9 or 10 in the form of a tube having one or more channels.
  - 12. The implant as claimed in either of claims 9 or 10 in the form of a heart valve.

13. A surgical aid intended to be fixed in and on the human or animal body, comprising the biocompatible block copolymer as claimed in any of the preceding

claims.

35

- 14. The diol as claimed in claim 1, obtainable by transesterification of  $\alpha, \omega$ -dihydroxy-[oligo(3-(R)-hydroxybutyrate)-ethylene-oligo-(3R)-hydroxybutyrate) with diglycolide.
- 15.  $\alpha, \omega$ -Dihydroxy-[oligo(3-R-hydroxybutyrate)-stat-glycolide)-ethylene-oligo-(3R)-hydroxybutyrate-stat-glycolide) as diol as claimed in claim 14.

5

10

- 16. A process for preparing a diol as claimed in claim 14, characterized in that  $\alpha, \omega$ -dihydroxy-[oligo(3-R-hydroxybutyrate)-ethylene-oligo-3-(R)-hydroxybutyrate) is reacted with diglycolide and/or dilactide and/or caprolactone or mixtures thereof.
- 17. The process as claimed in claim 16, characterized in that the reaction is carried out in the presence of a catalyst.
- 18. The process as claimed in either of claims 16 or 17, characterized in that the diol is dissolved in methylene chloride for purification, and impurities are removed.